235 related articles for article (PubMed ID: 8875984)
1. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
2. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the DNA binding characteristics of the related zinc finger proteins WT1 and EGR1.
Hamilton TB; Borel F; Romaniuk PJ
Biochemistry; 1998 Feb; 37(7):2051-8. PubMed ID: 9485332
[TBL] [Abstract][Full Text] [Related]
4. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
5. Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one.
Ladomery M; Sommerville J; Woolner S; Slight J; Hastie N
J Cell Sci; 2003 Apr; 116(Pt 8):1539-49. PubMed ID: 12640038
[TBL] [Abstract][Full Text] [Related]
6. New insights into DNA-binding behavior of Wilms tumor protein (WT1)--a dual study.
Nurmemmedov E; Yengo RK; Uysal H; Karlsson R; Thunnissen MM
Biophys Chem; 2009 Dec; 145(2-3):116-25. PubMed ID: 19853363
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
[TBL] [Abstract][Full Text] [Related]
8. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
9. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations.
Little M; Holmes G; Bickmore W; van Heyningen V; Hastie N; Wainwright B
Hum Mol Genet; 1995 Mar; 4(3):351-8. PubMed ID: 7795587
[TBL] [Abstract][Full Text] [Related]
10. +P5 (D1S3309E), a novel target binding site for the Wilms' tumour suppressor 1 (WT1) gene, maps to human chromosome 1q21-->22.
Negus K; Holmes GH; Wicking C; Wainwright BJ; Little MH
Cytogenet Cell Genet; 1996; 72(4):306-9. PubMed ID: 8641136
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor.
Menke AL; Shvarts A; Riteco N; van Ham RC; van der Eb AJ; Jochemsen AG
Cancer Res; 1997 Apr; 57(7):1353-63. PubMed ID: 9102224
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.
Sakamoto Y; Yoshida M; Semba K; Hunter T
Oncogene; 1997 Oct; 15(17):2001-12. PubMed ID: 9366517
[TBL] [Abstract][Full Text] [Related]
13. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
McCoy C; McGee SB; Cornwell MM
Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
[TBL] [Abstract][Full Text] [Related]
14. The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain.
Morrison AA; Venables JP; Dellaire G; Ladomery MR
Biochem Cell Biol; 2006 Oct; 84(5):789-98. PubMed ID: 17167543
[TBL] [Abstract][Full Text] [Related]
15. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
[TBL] [Abstract][Full Text] [Related]
16. Novel replication inhibitory function of the developmental regulator/transcription repressor protein WT1 encoded by the Wilms' tumor gene.
Anant S; Axenovich SA; Madden SL; Rauscher FJ; Subramanian KN
Oncogene; 1994 Nov; 9(11):3113-26. PubMed ID: 7936634
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors.
Liu J; Nau MM; Yeh JC; Allegra CJ; Chu E; Wright JJ
Clin Cancer Res; 2000 Sep; 6(9):3522-9. PubMed ID: 10999739
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
19. DNA-induced alpha-helix capping in conserved linker sequences is a determinant of binding affinity in Cys(2)-His(2) zinc fingers.
Laity JH; Dyson HJ; Wright PE
J Mol Biol; 2000 Jan; 295(4):719-27. PubMed ID: 10656784
[TBL] [Abstract][Full Text] [Related]
20. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
